ASTS
AST SpaceMobile, Inc.
ASTS has a slight edge over CREX overall, supported by stronger fundamentals and stronger modeled upside.
CREX
Creative Realities, Inc.
CREX has lower modeled downside risk, despite its lower overall score.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CREX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Stable |
CREX's revenue is currently strong, and its balance sheet is stable, but its profitability and cash flow are weak.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
CREX PE Valuation
CREX has no meaningful PE right now: it lost money over the past year.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
CREX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CREX's losses to shrink, with revenue growing.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS has the edge over CREX on earnings, with more consistent year-over-year improvement.
CREX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.11 | -$1.99 |
| Q1 2026 | -$1.87 | -$1.86 |
| Q4 2025 | -$0.81 | -$0.47 |
| Q3 2025 | -$0.88 | -729% |
| Q2 2025 | -$0.12 | -$0.03 |
| Q1 2025 | -$0.01 | +$0.21 |
| Q4 2024 | -$0.34 | +$0.01 |
| Q3 2022 | $0.15 | -55% |
CREX is still losing money, but far less than before: $2.11 per share over the past year, against $5.16 at its worst in late 2020.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over CREX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
CREX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $21.5M | +65% |
| Q1 2026 | $16.3M | +68% |
| Q4 2025 | $23.9M | +117% |
| Q3 2025 | $10.5M | -27% |
| Q2 2025 | $13M | -0.6% |
| Q1 2025 | $9.7M | -21% |
| Q4 2024 | $11M | -24% |
| Q3 2024 | $14.4M | +25% |
CREX's revenue is recovering but still below its 2022 peak: $22M last quarter, up 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -13% | -2.5 points |
| Q1 2026 | -38% | -31 points |
| Q4 2025 | 1.9% | +8.4 points |
| Q3 2025 | -69% | -77 points |
| Q2 2025 | -10% | -15 points |
| Q1 2025 | -7.4% | -6.8 points |
| Q4 2024 | -6.5% | -20 points |
| Q3 2024 | 7.9% | +6.5 points |
CREX has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
CREX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $457K | -32% |
| Q1 2026 | -$1.9M | +$551K |
| Q4 2025 | -$7M | -$5.6M |
| Q3 2025 | -$1.7M | -415% |
| Q2 2025 | $672K | -70% |
| Q1 2025 | -$2.5M | -227% |
| Q4 2024 | -$1.4M | +$1.8M |
| Q3 2024 | $543K | -71% |
CREX has the edge over ASTS on cash flow, with more consistent year-over-year improvement.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has 300M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
CREX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +16K shares |
| 1 year | +1.2% | +121K shares |
| 3 years | +44% | +3.2M shares |
| 5 years | +211% | +7.2M shares |
CREX has the edge over ASTS on shareholder dilution, with a more favorable share count trend.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CREX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | 2.1x | Moderate |
| Q4 2023 | 2.3x | Moderate |
| Q3 2023 | 4.8x | High |
| Q2 2023 | 13.2x | High |
| Q1 2023 | 10.0x | High |
| Q4 2022 | 45.2x | High |
| Q4 2019 | 4.9x | High |
CREX's net debt is about 2.1 years of its operating earnings (EBITDA), down from 10 years a year ago.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
CREX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 8.9 | Oversold |
CREX's weekly RSI is 33 (neutral) and its Stochastic is 9 (oversold).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
CREX PE vs Technology Sector
| Metric | CREX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
CREX has no meaningful PE right now: it lost money over the past year.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has the edge over CREX on trend strength, trading above more of its moving averages.
CREX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.25 | 4.4% below |
| 20 week MA | $2.79 | 23% below |
| 50 week MA | $3.20 | 33% below |
| 100 week MA | $2.87 | 25% below |
| 200 week MA | $2.98 | 28% below |
CREX is in a downtrend: it's below all five of its weekly moving averages, and 28% below its 200-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
CREX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.20 | $3.90 | -7.1% |
| 2021 | $3.90 | $4.38 | +12% |
| 2022 | $4.38 | $1.71 | -61% |
| 2023 | $1.71 | $2.36 | +38% |
| 2024 | $2.36 | $2.69 | +14% |
| 2025 | $2.69 | $2.66 | -1.1% |
| 2026 YTD | $2.66 | $2.15 | -19% |
CREX has the edge over ASTS on returns for 2026, with the stronger performance.